Board of Directors of Artgen Biotech terminated the agreement with Natsimbio on joint development of RBT vaccine for influenza and covid prophylaxis due to the delay in terms of organizing and conducting clinical trials. Ministry of Health allowed to conduct studies until December 31, 2024, but they never took place. Now RBT will independently prepare a dossier for the drug, obtain permission from the Ministry of Health for clinical trials and conduct them.